SEC Filing Analysis: Tango Therapeutics, Inc. (TNGX)

Executive Summary

• Trading Significance: Medium
• Key Takeaway: Director Malte Peters was granted 150,000 stock options, representing a potential 0.13% dilution to current shareholders upon exercise.
• Market Impact: Neutral. This is a standard form of non-cash compensation and does not reflect an insider's market sentiment through an open-market transaction.

Company Information

Field	Value
Company	Tango Therapeutics, Inc.
Ticker Symbol	TNGX
CIK	0001819133
Industry	Pharmaceutical Preparations

Insider Information

Field	Value
Name	Peters Malte
CIK	0001876563
Title/Position	null
Relationship	Director

Transaction Details

Field	Value
Form Type	4
Transaction Date	2025-11-03
Transaction Code	A (Grant)
Security Type	Stock Option (Right to Buy)
Shares Involved	150,000
Price Per Share	$0.00
Total Value	$0
Shares Owned After	150,000 (options)
Ownership Type	Direct

Financial Impact Assessment

Transaction Materiality

Metric	Value
Transaction Value	$0
% of Market Cap	0.00%
Shares Transacted	150,000
% of Shares Outstanding	0.135%
Post-Transaction Ownership	150,000 options (0.135% of outstanding if exercised)
Materiality Assessment	Moderate

Impact Evaluation

• Market Cap Context: For Tango Therapeutics, a company with a market capitalization of $1.06 billion, this equity grant is a standard operational expense for executive/director compensation and does not represent a significant capital event.
• Ownership Concentration: This grant establishes an initial equity-based position for the director. Post-transaction, Malte Peters holds no common stock directly but has the right to acquire 150,000 shares.
• Dilution Impact: The grant of 150,000 options represents a potential future dilution of 0.135% against the 111,260,247 shares outstanding. While not immediate, this is a tangible increase in the total potential share count that investors should be aware of.
• Transaction Significance: The significance is rated 'Medium' not due to the dollar value (which is $0 for a grant) but because the number of potential shares represents a moderate (0.135%) level of dilution. It provides a clear signal of the board's compensation strategy for new directors.

Market Impact Analysis

Stock Impact Prediction

• Direction: Neutral
• Reasoning: This is a scheduled compensation event (a grant), not an open-market purchase or sale. It does not signal an insider's bullish or bearish view on the stock's current valuation.

Volume & Sentiment

• Expected Volume Impact: Low. No shares were traded on the open market, so there is no direct impact on trading volume.
• Sentiment Indicator: Neutral. Equity grants are a routine part of corporate governance and compensation to align leadership with shareholder interests.

Investment Insights

Positive Market Indicators

• Aligns the new director's interests with long-term shareholder value creation, as the options' value is tied to future stock performance.

Risk Factors

• Introduces a potential 0.135% dilution for existing shareholders if and when the options are exercised.
• The exercise price is $8.01, meaning the stock price must appreciate above this level for the options to have intrinsic value for the holder.

Key Takeaways

1. Director Compensation: A new director, Malte Peters, received a standard but notable stock option grant.
2. Potential Dilution: The grant represents a 0.135% potential increase in shares outstanding, a moderate level of dilution.
3. Vesting Schedule: The options are not immediately available; they vest in 48 equal monthly installments over four years, encouraging long-term commitment.

Additional Context

Transaction Notes

• Special Circumstances: As per footnote 1, the options vest monthly over a four-year period, contingent upon the director's continuous service. This structure is designed to retain talent and ensure long-term alignment.